Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veri Medtech Holdings's yield on cost for the quarter that ended in Dec. 2021 was 0.00.
The historical rank and industry rank for Veri Medtech Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
VRHI's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.9 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Veri Medtech Holdings (OTCPK:VRHI) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Veri Medtech Holdings 5-Year Yield-on-Cost % Related Terms
VRHI vs MMVVF, BLMZ, MVNC: 5-Year Yield-on-Cost % Comparison
For the Health Information Services subindustry, Veri Medtech Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veri Medtech Holdings 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veri Medtech Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Veri Medtech Holdings's 5-Year Yield-on-Cost % falls into.
Veri Medtech Holdings 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Veri Medtech Holdings (VRHI) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Veri Medtech Holdings and its competitors.
Is Veri Medtech Holdings' 5-Year Yield-on-Cost % too high?
Veri Medtech Holdings' current 5-Year Yield-on-Cost % is 0.00. Overall, Veri Medtech Holdings has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Veri Medtech Holdings' 5-Year Yield-on-Cost % compare to MMVVF and BLMZ?
Veri Medtech Holdings' 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Healthcare Providers & Services industry. The industry median 5-Year Yield-on-Cost % is 2.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Veri Medtech Holdings and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veri Medtech Holdings's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veri Medtech Holdings stock overvalued right now?
Veri Medtech Holdings (VRHI) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Veri Medtech Holdings' overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Veri Medtech Holdings (VRHI), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Veri Medtech Holdings Inc is a healthcare technology company that offers alternative medicine, personalized diagnostics, and wellness medication on demand. The company leverages telehealth infrastructure, diagnostic intelligence, and scalable digital systems to meet the growing demand for accessible, stigma-free healthcare. Strategically positioned for growth, Veri MedTech actively explores acquisitions that complement its core capabilities and enhance patient engagement across emerging sectors of alternative medicine, longevity, and wellness science. With an integration and operational efficiency track record, the company drives accelerated revenue through the continuous generation of high-value patient databases and recurring service models.
35GF Score
Get the complete analysis for VRHI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRHI has been successfully added to your 
